SCHEMBL4048338

SCHEMBL4048338

Cc1cc(C=O)ccc1-c1noc(-c2ccc(OC(C)C)c(C(F)(F)F)c2)n1

nearest known ligand 0.67

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 18/20 0.67
S1PR5 Q9H228 12/20 0.67
S1PR3 Q99500 11/20 0.67
DYRK3 O43781 1/20 0.47
MAP4K4 O95819 1/20 0.47
ERBB2 P04626 1/20 0.47
PIM1 P11309 1/20 0.47
MARK3 P27448 1/20 0.47
PLK1 P53350 1/20 0.47
CAMK2B Q13554 1/20 0.47
CDC42BPA Q5VT25 1/20 0.47
PIM3 Q86V86 1/20 0.47
MINK1 Q8N4C8 1/20 0.47
SRPK1 Q96SB4 1/20 0.47
MKNK2 Q9HBH9 1/20 0.47
MAP3K20 Q9NYL2 1/20 0.47
MAP4K5 Q9Y4K4 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4046816 0.90 S1PR1 (0.64) S1PR1S1PR5S1PR3
SCHEMBL28644869 0.90 S1PR1 (0.56) S1PR1S1PR5S1PR3DYRK3MAP4K4
SCHEMBL4951756 0.88 S1PR1 (0.55) S1PR1S1PR5S1PR3DYRK3MAP4K4
SCHEMBL4360513 0.87 S1PR1 (0.68) S1PR1S1PR5S1PR3DYRK3MAP4K4
SCHEMBL4360487 0.87 S1PR1 (0.68) S1PR1S1PR5S1PR3DYRK3MAP4K4
SCHEMBL3956707 0.86 S1PR1 (0.68) S1PR1S1PR5S1PR3
SCHEMBL27669749 0.84 S1PR1 (0.62) S1PR1S1PR5S1PR3DYRK3MAP4K4
SCHEMBL4041286 0.80 S1PR1 (0.74) S1PR1S1PR5S1PR3
SCHEMBL13678382 0.80 S1PR1 (0.76) S1PR1S1PR5S1PR3DYRK3MAP4K4
SCHEMBL13678378 0.80 S1PR1 (0.79) S1PR1S1PR5S1PR3DYRK3MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7605171-B2 (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists MERCK & CO., INC. (US) 2009-10-20 US disclosed
EP-1697333-A4 (3,4-DISUBSTITUTED)PROPANOIC CARBOXYLATES AS S1P (EDG) RECEPTOR AGONISTS MERCK & CO INC (US) 2009-07-08 EP disclosed
US-20080249093-A1 (3,4-Disubstituted)Propanoic Carboxylates as Sip (Edg) Receptor Agonists MERCK & CO., INC. (US) 2008-10-09 US disclosed
CN-1894225-A (3, 4-disubstituted) propanoates as sphingosine 1-phosphate (endothelial differentiation gene) receptor agonists MERCK & CO INC (US) 2007-01-10 CN disclosed
EP-1697333-A1 (3,4-DISUBSTITUTED)PROPANOIC CARBOXYLATES AS S1P (EDG) RECEPTOR AGONISTS Merck & Co., Inc. (US) 2006-09-06 EP disclosed
WO-2005058848-A1 (3,4-DISUBSTITUTED)PROPANOIC CARBOXYLATES AS S1P (EDG) RECEPTOR AGONISTS MERCK & CO., INC. (US) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080249093-A1 (3,4-Disubstituted)Propanoic Carboxylates as Sip (Edg) Receptor Agonists S1PR1, S1PR3, S1PR5 S1PR1 1/4885S1PR5 3/4885S1PR3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.